Aastrom Biosciences: Journal of Vascular Surgery Publishes Interim Results of RESTORE-CLI Phase 2b Clinical Trial

Aastrom Biosciences ASTM today announced that data from the Phase 2b RESTORE-CLI clinical trial of ixmyelocel-T have been published in the peer-reviewed Journal of Vascular Surgery. Richard J. Powell, M.D., section chief of vascular surgery at the Dartmouth-Hitchcock Medical Center in Lebanon, NH, and a principal investigator of the RESTORE-CLI clinical trial, is lead author on the publication. "The publication of interim data from the RESTORE-CLI trial in the Journal of Vascular Surgery reflects Aastrom's commitment to peer-review and is another important validation of the strong results from our clinical program for ixmyelocel-T. We thank Dr. Powell and all of our investigators for their important and continuing contributions to this effort, and we look forward to initiating our Phase 3 REVIVE-CLI clinical program for ixmyelocel-T in the near future," said Tim Mayleben, president and CEO of Aastrom. The 6-month interim findings from the RESTORE-CLI Phase 2b clinical trial were reported previously by Aastrom in February 2010 and were also presented at the Society for Vascular Surgery Annual Meeting in June 2010. Aastrom reported the final top line results of this trial in June 2011 and is submitting the full data for presentation at a major medical meeting later this year.